Advertisement

Fatigue

  • Martin MückeEmail author
  • Dmitrij Kravchenko
Reference work entry

Abstract

Fatigue is a subjective multidimensional illness that plays an immense role, sometimes having an even greater impact than symptoms such as pain, nausea, and vomiting, in a patient’s quality of life. Once treatable causes for fatigue are excluded, a multimodal therapy plan should be developed with considerations toward the wishes and preferences of the patient. Research suggests that feelings of physical well-being and emotional stability are the most important aspects with respect to the quality of life, regardless of cultural and individual differences. Similarly, the social integration of the patient and their ability to self-reliantly live out their day-to-day life is also of great importance.

References

  1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.CrossRefGoogle Scholar
  2. Bausewein C, Daveson BA, Currow DC, Downing J, Deliens L, Radbruch L, Defilippi K, et al. EAPC white paper on outcome measurement in palliative care: improving practice, attaining outcomes and delivering quality services – recommendations from the European Association for Palliative Care (EAPC) task force on outcome measurement. Palliat Med. 2016;30(1):6–22.  https://doi.org/10.1177/0269216315589898.CrossRefPubMedGoogle Scholar
  3. Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C, et al. Cancer-related fatigue, version 2.2015. J Natl Compr Cancer Netw. 2015;13(8):1012–39.CrossRefGoogle Scholar
  4. Bower JE, Lamkin DM. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun. 2013;30(0):S48–57.  https://doi.org/10.1016/j.bbi.2012.06.011.CrossRefPubMedGoogle Scholar
  5. Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T, Lynn Palmer J. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(13):2073–8.  https://doi.org/10.1200/JCO.2005.02.8506.CrossRefGoogle Scholar
  6. Butler JM, Douglas Case L, Atkins J, Frizzell B, Sanders G, Griffin P, Lesser G, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of D-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2007;69(5):1496–501.  https://doi.org/10.1016/j.ijrobp.2007.05.076.CrossRefPubMedGoogle Scholar
  7. Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. Progress toward guidelines for the management of fatigue. Oncology (Williston Park). 1998;12(11A): 369–77.Google Scholar
  8. Cella D, Davis K, Breitbart W, Curt G, Coalition F. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(14):3385–91.  https://doi.org/10.1200/JCO.2001.19.14.3385.CrossRefGoogle Scholar
  9. Collado-Hidalgo A, Bower JE, Ganz PA, Irwin MR, Cole SW. Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings. Brain Behav Immun. 2008;22(8):1197–200.  https://doi.org/10.1016/j.bbi.2008.05.009.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Board on the Health of Select Populations, and Institute of Medicine. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness. The national academies collection: reports Funded by National Institutes of Health. Washington, DC: National Academies Press (US); 2015. http://www.ncbi.nlm.nih.gov/books/NBK274235/.
  11. Davis M, Lasheen W, Walsh D, Mahmoud F, Bicanovsky L, Lagman R. A phase II dose titration study of thalidomide for cancer-associated anorexia. J Pain Symptom Manag. 2012;43(1):78–86.  https://doi.org/10.1016/j.jpainsymman.2011.03.007.CrossRefGoogle Scholar
  12. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95.  https://doi.org/10.1016/S1470-2045(10)70218-7.CrossRefPubMedGoogle Scholar
  13. Glaus A. Fatigue in patients with cancer. Vol. 145. Recent Results in Cancer Research. Berlin: Springer; 1998.  https://doi.org/10.1007/978-3-642-51466-1.CrossRefGoogle Scholar
  14. Hilfiker R, Meichtry A, Eicher M, Nilsson BL, Knols RH, Verra ML, Taeymans J. Exercise and other non-pharmaceutical interventions for cancer-related fatigue in patients during or after cancer treatment: a systematic review incorporating an indirect-comparisons meta-analysis. Br J Sports Med. 2017.  https://doi.org/10.1136/bjsports-2016-096422.CrossRefGoogle Scholar
  15. Jocham HR, Dassen T, Widdershoven G, Halfens R. Reliability and validity of the EORTC QLQ-C30 in palliative care cancer patients. Cent Eur J Med. 2009;4(3):348–57.  https://doi.org/10.2478/s11536-009-0032-7.CrossRefGoogle Scholar
  16. Kamath J, Yarbrough GG, Prange AJ, Winokur A. Thyrotropin-releasing hormone can relieve cancer-related fatigue: hypothesis and preliminary observations. J Int Med Res. 2009;37(4):1152–7.  https://doi.org/10.1177/147323000903700420.CrossRefPubMedGoogle Scholar
  17. Lange R, Volkmer M, Heesen C, Liepert J. Modafinil effects in multiple sclerosis patients with fatigue. J Neurol. 2009;256(4):645–50.  https://doi.org/10.1007/s00415-009-0152-7.CrossRefPubMedGoogle Scholar
  18. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. JNCI Monogr. 2004;2004(32):40–50.  https://doi.org/10.1093/jncimonographs/lgh027.CrossRefGoogle Scholar
  19. Marvibaigi M, Supriyanto E, Amini N, Majid FAA, Jaganathan SK. Preclinical and clinical effects of mistletoe against breast cancer. Bio Med Res Int. 2014.  https://doi.org/10.1155/2014/785479.CrossRefGoogle Scholar
  20. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL. The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer. 1999;85(5):1186–96.CrossRefGoogle Scholar
  21. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy for the management of cancer-related fatigue. In: Cochrane database of systematic reviews: Wiley; 2010.  https://doi.org/10.1002/14651858.CD006704.pub3.
  22. Mochamat MM, Cuhls H, Conrad R, Kravchenko D, Radbruch L. Non-pharmacological treatments for fatigue in advanced disease associated with palliative care: a systematic review. (Unpublished data).Google Scholar
  23. Mochamat, Cuhls H, Marinova M, Kaasa S, Stieber C, Conrad R, Radbruch L, Mücke M. A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a European Palliative Care Research Centre cachexia project. J Cachexia Sarcopenia Muscle. 2017;8(1):25–39.  https://doi.org/10.1002/jcsm.12127. Epub 2016 Jul 20. Review. PubMed PMID: 27897391; PubMed Central PMCID: PMC5326814.CrossRefGoogle Scholar
  24. Morrow GR, Hickok JT, Roscoe JA, Raubertas RF, Andrews PLR, Flynn PJ, Hynes HE, Banerjee TK, Kirshner JJ, King DK. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 2003;21(24):4635–41.  https://doi.org/10.1200/JCO.2003.04.070.CrossRefPubMedGoogle Scholar
  25. Mücke M, Mochamat HC, Peuckmann-Post V, Minton O, Stone P, Radbruch L. Pharmacological treatments for fatigue associated with palliative care: executive summary of a Cochrane Collaboration systematic review. J Cachexia Sarcopenia Muscle. 2016;7(1):23–7.  https://doi.org/10.1002/jcsm.12101.CrossRefPubMedPubMedCentralGoogle Scholar
  26. Questionnaires | EORTC. 2017. http://groups.eortc.be/qol/eortc-qlq-c30. Accessed 25 May.
  27. Radad K, Moldzio R, Rausch W-D. Ginsenosides and their CNS targets. CNS Neurosci Ther. 2011;17(6):761–8.  https://doi.org/10.1111/j.1755-5949.2010.00208.x.CrossRefPubMedGoogle Scholar
  28. Radbruch L, Strasser F, Elsner F, Gonçalves JF, Løge J, Kaasa S, Nauck F, Stone P. Fatigue in palliative care patients – an EAPC approach. Palliat Med. 2008;22(1):13–32.  https://doi.org/10.1177/0269216307085183.CrossRefPubMedGoogle Scholar
  29. Rasheed N, Tyagi E, Ahmad A, Siripurapu KB, Lahiri S, Shukla R, Palit G. Involvement of monoamines and proinflammatory cytokines in mediating the anti-stress effects of panax quinquefolium. J Ethnopharmacol. 2008;117(2):257–62.  https://doi.org/10.1016/j.jep.2008.01.035.CrossRefPubMedGoogle Scholar
  30. Reid J, Mills M, Cantwell M, Cardwell CR, Murray LJ, Donnelly M. Thalidomide for managing cancer cachexia. In: Cochrane database of systematic reviews: Wiley; 2012.  https://doi.org/10.1002/14651858.CD008664.pub2.
  31. Safari R, Van der Linden ML, Mercer TH. Effect of exercise interventions on perceived fatigue in people with multiple sclerosis: synthesis of meta-analytic reviews. Neurodegener Dis Manag. 2017;7(3): 219–30.  https://doi.org/10.2217/nmt-2017-0009.CrossRefPubMedGoogle Scholar
  32. Shaygannejad V, Janghorbani M, Ashtari F, Zakeri H. Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurol Res. 2012;34(9):854–8.  https://doi.org/10.1179/1743132812Y.0000000081.CrossRefPubMedGoogle Scholar
  33. Shih A, Jackson KC. Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother. 2007;21(4):69–76.CrossRefGoogle Scholar
  34. Spathis A, Fife K, Blackhall F, Dutton S, Bahadori R, Wharton R, O’Brien M, et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(18):1882–8.  https://doi.org/10.1200/JCO.2013.54.4346.CrossRefGoogle Scholar
  35. Stark L, Tofthagen C, Visovsky C, McMillan SC. The symptom experience of patients with cancer. J Hosp Palliat Nurs. 2012;14(1):61–70.  https://doi.org/10.1097/NJH.0b013e318236de5c.CrossRefPubMedPubMedCentralGoogle Scholar
  36. Stiel S, Matthes ME, Bertram L, Ostgathe C, Elsner F, Radbruch L. Validierung der neuen Fassung des Minimalen Dokumentationssystems (MIDOS2) für Patienten in der Palliativmedizin. Der Schmerz. 2010;24(6):596–604.  https://doi.org/10.1007/s00482-010-0972-5.CrossRefPubMedGoogle Scholar
  37. Stone PC, Minton O. Cancer-related fatigue. Eur J Cancer Palliat Med Art Sci. 2008;44(8):1097–104.  https://doi.org/10.1016/j.ejca.2008.02.037.CrossRefGoogle Scholar
  38. Wang XS. Pathophysiology of cancer-related fatigue. Clin J Oncol Nurs. 2008;12(5 Suppl):11–20.  https://doi.org/10.1188/08.CJON.S2.11-20.CrossRefPubMedPubMedCentralGoogle Scholar
  39. Ware JE. SF-36 health survey update. LWW Spine. 2000;25(24):3130–9.CrossRefGoogle Scholar
  40. Wingerchuk DM, Benarroch EE, O’Brien PC, Keegan BM, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology. 2005;64(7):1267–9.  https://doi.org/10.1212/01.WNL.0000156803.23698.9A.CrossRefPubMedGoogle Scholar
  41. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13(2):63–74.  https://doi.org/10.1016/S0885-3924(96)00274-6.CrossRefGoogle Scholar
  42. Yennurajalingam S, Willey JS, Lynn Palmer J, Allo J, Del Fabbro E, Cohen EN, Tin S, Reuben JM, Bruera E. The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. J Palliat Med. 2012;15(10):1059–64.  https://doi.org/10.1089/jpm.2012.0146.CrossRefPubMedPubMedCentralGoogle Scholar
  43. Yennurajalingam S, Susan F-H, Lynn Palmer J, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31(25):3076–82.  https://doi.org/10.1200/JCO.2012.44.4661.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Palliative MedicineUniversitätsklinikum Bonn (AöR)BonnGermany

Personalised recommendations